SciELO - Scientific Electronic Library Online

 
vol.13 issue2Pericarditis y Pericardiectomía: Experiencia en el Hospital R. A. Calderón Guardia, 2003-2010 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Costarricense de Cardiología

Print version ISSN 1409-4142

Abstract

WHAYNE, JR, Thomas F. ¿Es la Pitavastatina una estatina más o un nuevo fármaco ventajoso?. Rev. costarric. cardiol [online]. 2011, vol.13, n.2, pp.13-14. ISSN 1409-4142.

There are currently 7 statins available in clinical practice. Pitavastatin is the newest statin and it appears to have significant advantages for the patient who has not tolerated other statins. With pitavastatin, there is a smaller decrease in coenzyme Q-10 which may diminish the risk of myopathy. Also, pitavastatin does not depend on cytochrome P450 for its metabolism and this decreases the risk for metabolic alterations. In addition, pitavastatin offers the possibility of a larger increase in high density lipoproteins. Therefore, its usage appears justified in certain circumstances and it appears that pitavastatin may have a unique niche in decreasing cardiovascular risk.

Keywords : pitavastatin; myopathy; lipoprotein.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License